Working under pressure: Coronary arteries and the endothelin system

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 298, Issue 5, 2010, Pages

  Nguyen, Albert ^a   Thorin Trescases, Nathalie ^a   Thorin, Eric ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Coronary blood flow; Inflammation; Shear stress; Vascular tone

Indexed keywords

ANGIOTENSIN II; BRADYKININ; CGS 35601; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; NITRIC OXIDE; UNCLASSIFIED DRUG;

AGING; BLOOD VESSEL TONE; CORONARY ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY SPASM; ENZYME INHIBITION; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SHEAR STRESS; VASCULAR ENDOTHELIUM; VASOCONSTRICTION;

EID: 77951761340     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00653.2009     Document Type: Review

References (75)

1. Adlbrecht C, Bonderman D, Plass C, Jakowitsch J, Beran G, Sperker W, Siostrzonek P, Glogar D, Maurer G, Lang IM. Active endothelin is an important vasoconstrictor in acute coronary thrombi. Thromb Haemost 97: 642-649, 2007. (Pubitemid 46592943)
2. Alonso D, Radomski MW. The nitric oxide-endothelin-1 connection. Heart Fail Rev 8: 107-115, 2003.
3. Angerio AD. The role of endothelin in heart failure. Crit Care Nurs Q 28: 355-359, 2005.
4. Anggrahini DW, Emoto N, Nakayama K, Widyantoro B, Adiarto S, Iwasa N, Nonaka H, Rikitake Y, Kisanuki YY, Yanagisawa M, Hirata K. Vascular endothelial cell-derived endothelin-1 mediates vascular inflammation and neointima formation following blood flow cessation. Cardiovasc Res 82: 143-151, 2009.
5. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348: 730-732, 1990. (Pubitemid 120015147)
6. Bacon CR, Cary NR, Davenport AP. Endothelin peptide and receptors in human atherosclerotic coronary artery and aorta. Circ Res 79: 794-801, 1996. (Pubitemid 26317827)
7. Bacon CR, Davenport AP. Endothelin receptors in human coronary artery and aorta. Br J Pharmacol 117: 986-992, 1996. (Pubitemid 26075978)
8. Barton M, Haudenschild CC, d'Uscio LV, Shaw S, Munter K, Luscher TF. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 95: 14367-14372, 1998. (Pubitemid 28549373)
9. Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol 86: 485-498, 2008.
10. Benigni A, Remuzzi G. Endothelin antagonists. Lancet 353: 133-138, 1999.
11. Bohm F, Jensen J, Svane B, Settergren M, Pernow J. Intracoronary endothelin receptor blockade improves endothelial function in patients with coronary artery disease. Can J Physiol Pharmacol 86: 745-751, 2008.
12. Boulanger C, Luscher TF. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 85: 587-590, 1990. (Pubitemid 20070070)
13. Brunner F. Interaction of nitric oxide and endothelin-1 in ischemia/reperfusion injury of rat heart. J Mol Cell Cardiol 29: 2363-2374, 1997. (Pubitemid 27404429)
14. Brunner F. Tissue endothelin-1 levels in perfused rat heart following stimulation with agonists and in ischaemia and reperfusion. J Mol Cell Cardiol 27: 1953-1963, 1995.
15. Brunner F, Bras-Silva C, Cerdeira AS, Leite-Moreira AF. Cardiovascular endothelins: essential regulators of cardiovascular homeostasis. Pharmacol Ther 111: 508-531, 2006. (Pubitemid 43832003)
16. Brunner F, Stessel H, Kukovetz WR. Novel guanylyl cyclase inhibitor, ODQ reveals role of nitric oxide, but not of cyclic GMP in endothelin-1 secretion. FEBS Lett 376: 262-266, 1995.
17. Callera G, Tostes R, Savoia C, Muscara MN, Touyz RM. Vasoactive peptides in cardiovascular (patho)physiology. Expert Rev Cardiovasc Ther 5: 531-552, 2007.
18. Celebi H, Catakoglu AB, Kurtoglu H, Sener M, Hanavdelogullari R, Demiroglu C, Aytekin V, Aytekin S. The relation between coronary flow rate, plasma endothelin-1 concentrations, and clinical characteristics in patients with normal coronary arteries. Cardiovasc Revasc Med 9: 144-148, 2008. (Pubitemid 351905941)
19. Climent B, Fernandez N, Sanz E, Sanchez A, Monge L, Garcia-Villalon AL, Dieguez G. Enhanced response of pig coronary arteries to endothelin-1 after ischemia-reperfusion. Role of endothelin receptors, nitric oxide and prostanoids. Eur J Pharmacol 524: 102-110, 2005. (Pubitemid 41606821)
20. D'Orleans-Juste P, Labonte J, Bkaily G, Choufani S, Plante M, Honore JC. Function of the endothelin(B) receptor in cardiovascular physiology and pathophysiology. Pharmacol Ther 95: 221-238, 2002. (Pubitemid 35247902)
21. Dagassan PH, Breu V, Clozel M, Kunzli A, Vogt P, Turina M, Kiowski W, Clozel JP. Up-regulation of endothelin-B receptors in atherosclerotic human coronary arteries. J Cardiovasc Pharmacol 27: 147-153, 1996. (Pubitemid 26013150)
22. Dancu MB, Tarbell JM. Coronary endothelium expresses a pathologic gene pattern compared to aortic endothelium: correlation of asynchronous hemodynamics and pathology in vivo. Atherosclerosis 192: 9-14, 2007.
23. Dashwood MR, Mehta D, Izzat MB, Timm M, Bryan AJ, Angelini GD, Jeremy JY. Distribution of endothelin-1 (ET) receptors (ET(A) and ET(B)) and immunoreactive ET-1 in porcine saphenous vein-carotid artery interposition grafts. Atherosclerosis 137: 233-242, 1998. (Pubitemid 28215869)
24. Dashwood MR, Timm M, Muddle JR, Ong AC, Tippins JR, Parker R, McManus D, Murday AJ, Madden BP, Kaski JC. Regional variations in endothelin-1 and its receptor subtypes in human coronary vasculature: pathophysiological implications in coronary disease. Endothelium 6: 61-70, 1998. (Pubitemid 28490875)
25. Dashwood MR, Tsui JC. Endothelin-1 and atherosclerosis: potential complications associated with endothelin-receptor blockade. Atherosclerosis 160: 297-304, 2002.
26. Daull P, Benrezzak O, Arsenault D, Pheng LH, Blouin A, Cayer J, Beaudoin M, Belleville K, Sirois P, Nantel F, Jeng AY, Battistini B. Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats. Am J Hypertens 18: 1606-1613, 2005. (Pubitemid 41814683)
27. Daull P, Jeng AY, Battistini B. Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases. J Cardiovasc Pharmacol 50: 247-256, 2007. (Pubitemid 47428971)
28. Davenport AP, Maguire JJ. The endothelin system in human saphenous vein graft disease. Curr Opin Pharmacol 1: 176-182, 2001.
29. Dong F, Zhang X, Wold LE, Ren Q, Zhang Z, Ren J. Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ETB receptor, NADPH oxidase and caveolin-1. Br J Pharmacol 145: 323-333, 2005. (Pubitemid 40896077)
30. Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV, Ohlstein EH, Willette RN. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 131: 1262-1274, 2000.
31. Fan J, Unoki H, Iwasa S, Watanabe T. Role of endothelin-1 in atherosclerosis. Ann NY Acad Sci 902: 84-93; discussion 93-184, 2000.
32. Garcia-Villalon AL, Amezquita YM, Monge L, Fernandez N, Salcedo A, Dieguez G. Endothelin-1 potentiation of coronary artery contraction after ischemia-reperfusion. Vascul Pharmacol 48: 109-114, 2008.
33. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 20: 2175-2183, 2000.
34. Halcox JP, Nour KR, Zalos G, Quyyumi AA. Coronary vasodilation and improvement in endothelial dysfunction with endothelin ET(A) receptor blockade. Circ Res 89: 969-976, 2001. (Pubitemid 34640862)
35. Halcox JP, Nour KR, Zalos G, Quyyumi AA. Endogenous endothelin in human coronary vascular function: differential contribution of endothelin receptor types A and B. Hypertension 49: 1134-1141, 2007. (Pubitemid 351664308)
36. Hasdai D, Mathew V, Schwartz RS, Smith LA, Holmes DR Jr, Katusic ZS, Lerman A. Enhanced endothelin-B-receptor-mediated vasoconstriction of small porcine coronary arteries in diet-induced hypercholesterolemia. Arterioscler Thromb Vasc Biol 17: 2737-2743, 1997. (Pubitemid 28016016)
37. Heusch G. Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. Br J Pharmacol 153: 1589-1601, 2008. (Pubitemid 351535988)
38. Ihling C, Szombathy T, Bohrmann B, Brockhaus M, Schaefer HE, Loeffler BM. Coexpression of endothelin-converting enzyme-1 and endothelin-1 in different stages of human atherosclerosis. Circulation 104: 864-869, 2001.
39. Ivey ME, Osman N, Little PJ. Endothelin-1 signalling in vascular smooth muscle: pathways controlling cellular functions associated with atherosclerosis. Atherosclerosis 199: 237-247, 2008.
40. Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 41: 851-876, 2001. (Pubitemid 32385909)
41. Kelland NF, Webb DJ. Clinical trials of endothelin antagonists in heart failure: a question of dose? Exp Biol Med (Maywood) 231: 696-699, 2006. (Pubitemid 43845511)
42. Kinlay S, Behrendt D, Wainstein M, Beltrame J, Fang JC, Creager MA, Selwyn AP, Ganz P. Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries. Circulation 104: 1114-1118, 2001. (Pubitemid 32830393)
43. Kirkby NS, Hadoke PW, Bagnall AJ, Webb DJ. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 153: 1105-1119, 2008.
44. Kohno M, Horio T, Yokokawa K, Kurihara N, Takeda T. C-type natriuretic peptide inhibits thrombin- and angiotensin II-stimulated endothelin release via cyclic guanosine 3′,5′-monophosphate. Hypertension 19: 320-325, 1992.
45. Kourembanas S, McQuillan LP, Leung GK, Faller DV. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest 92: 99-104, 1993. (Pubitemid 23208985)
46. Kyriakides ZS, Kremastinos DT, Bofilis E, Tousoulis D, Antoniadis A, Webb DJ. Endogenous endothelin maintains coronary artery tone by endothelin type A receptor stimulation in patients undergoing coronary arteriography. Heart 84: 176-182, 2000.
47. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 325: 997-1001, 1991. (Pubitemid 23360220)
48. Liu Y, Gutterman DD. Vascular control in humans: focus on the coronary microcirculation. Basic Res Cardiol 104: 211-227, 2009.
49. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 315: 1046-1051, 1986.
50. Luscher TF, Yang Z, Tschudi M, von Segesser L, Stulz P, Boulanger C, Siebenmann R, Turina M, Buhler FR. Interaction between endothelin-1 and endothelium-derived relaxing factor in human arteries and veins. Circ Res 66: 1088-1094, 1990. (Pubitemid 20126439)
51. Maemura K, Kurihara H, Morita T, Oh-hashi Y, Yazaki Y. Production of endothelin-1 in vascular endothelial cells is regulated by factors associated with vascular injury. Gerontology 38 Suppl 1: 29-35, 1992.
52. Marsden PA, Brenner BM. Transcriptional regulation of the endothelin-1 gene by TNF-α. Am J Physiol Cell Physiol 262: C854-C861, 1992.
53. Osugi T, Saitoh SI, Matumoto K, Muto M, Aikawa K, Ohkawara H, Sugimoto K, Kamioka M, Ishibashi T, Maruyama Y. Preventive effect of chronic endothelin type A receptor antagonist on coronary microvascular spasm induced by repeated epicardial coronary artery endothelial denudation in pigs. J Atheroscler Thromb 17: 54-63, 2010.
54. Pierre LN, Davenport AP. Endothelin receptor subtypes and their functional relevance in human small coronary arteries. Br J Pharmacol 124: 499-506, 1998.
55. Prins BA, Hu RM, Nazario B, Pedram A, Frank HJ, Weber MA, Levin ER. Prostaglandin E2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells. J Biol Chem 269: 11938-11944, 1994. (Pubitemid 2072466)
56. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, pathophysiology. Pharmacol Rev 46: 325-415, 1994.
57. Ruschitzka F, Moehrlen U, Quaschning T, Lachat M, Noll G, Shaw S, Yang Z, Teupser D, Subkowski T, Turina MI, Luscher TF. Tissue endothelin-converting enzyme activity correlates with cardiovascular risk factors in coronary artery disease. Circulation 102: 1086-1092, 2000.
58. Saitoh S, Matsumoto K, Kamioka M, Ohkawara H, Kaneshiro T, Ishibashi T, Maruyama Y. Novel pathway of endothelin-1 and reactive oxygen species in coronary vasospasm with endothelial dysfunction. Coron Artery Dis 20: 400-408, 2009.
59. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 348: 732-735, 1990. (Pubitemid 120015148)
60. Sauvageau S, Thorin E, Caron A, Dupuis J. Endothelin-1-induced pulmonary vasoreactivity is regulated by ET(A) and ET(B) receptor interactions. J Vasc Res 44: 375-381, 2007. (Pubitemid 47312658)
61. Sauvageau S, Thorin E, Caron A, Dupuis J. Evaluation of endothelin-1-induced pulmonary vasoconstriction following myocardial infarction. Exp Biol Med (Maywood) 231: 840-846, 2006. (Pubitemid 43845538)
62. Sauvageau S, Thorin E, Villeneuve L, Dupuis J. Change in pharmacological effect of endothelin receptor antagonists in rats with pulmonary hypertension: role of ETB-receptor expression levels. Pulm Pharmacol Ther 22: 311-317, 2009.
63. Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 78: 539-552, 2009.
64. Stauffer BL, Westby CM, DeSouza CA. Endothelin-1, aging and hypertension. Curr Opin Cardiol 23: 350-355, 2008.
65. Teerlink JR, Breu V, Sprecher U, Clozel M, Clozel JP. Potent vasoconstriction mediated by endothelin ETB receptors in canine coronary arteries. Circ Res 74: 105-114, 1994. (Pubitemid 24976842)
66. Thorin E. Different contribution of endothelial nitric oxide in the relaxation of human coronary arteries of ischemic and dilated cardiomyopathic hearts. J Cardiovasc Pharmacol 37: 227-232, 2001. (Pubitemid 32106115)
67. Thorin E. Influence of nitric oxide synthase inhibition and endothelin-1 receptor blockade on acetylcholine-induced coronary artery contraction in vitro in dilated and ischemic cardiomyopathies. J Cardiovasc Pharmacol 38: 90-98, 2001. (Pubitemid 32634993)
68. Thorin E, Parent R, Ming Z, Lavallee M. Contribution of endogenous endothelin to large epicardial coronary artery tone in dogs and humans. Am J Physiol Heart Circ Physiol 277: H524-H532, 1999. (Pubitemid 29415965)
69. Thorin E, Thorin-Trescases N. Vascular endothelial ageing, heartbeat after heartbeat. Cardiovasc Res 84: 24-32, 2009.
70. Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ, Webb DJ. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 97: 752-756, 1998.
71. Vermeltfoort IA, Raijmakers PG, Kamphuisen PW. Improved myocardial perfusion preceding clinical response on bosentan treatment for coronary vasospasm. Acta Cardiol 64: 415-417, 2009.
72. Watts SW. Endothelin receptors: what's new and what do we need to know? Am J Physiol Regul Integr Comp Physiol 298: R254-R260, 2010.
73. Wedgwood S, Black SM. Endothelin-1 decreases endothelial NOS expression and activity through ETA receptor-mediated generation of hydrogen peroxide. Am J Physiol Lung Cell Mol Physiol 288: L480-L487, 2005. (Pubitemid 40229513)
74. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415, 1988. (Pubitemid 18090241)
75. Yang LL, Gros R, Kabir MG, Sadi A, Gotlieb AI, Husain M, Stewart DJ. Conditional cardiac overexpression of endothelin-1 induces in- flammation and dilated cardiomyopathy in mice. Circulation 109: 255-261, 2004. (Pubitemid 38114148)